FDA Rejects Proposed Xarelto Antidote
- Last Updated: August 4th, 2023
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
FDA Rejects Proposed Xarelto Antidote
Portola Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) failed to approve AndexXa, the Xarelto antidote currently in development for uncontrollable bleeds.
Currently, there is no reversal agent for uncontrolled bleeding associated with the anticoagulants Xarelto or Eliquis which have been linked to fatal brain and stomach bleeds.
Xarelto lawsuits continue to be filed.
Table of Contents
Xarelto Antidote
The application for the Xarelto Antidote, AndexXa was based on data from the two-phase III ANNEXA-A and ANNEXA-R trials.
Those studies, published in the New England Journal of Medicine, showed that AnderXa effectively reversed the anticoagulant activity of Eliquis and Xarelto in healthy volunteers with no serious adverse events.
Although the FDA granted AndexXa expedited review, the agency decided that it needs more information before the drug can be approved.
The FDA requested additional information describing the drug’s manufacturing process and said it needed to review changes Portola has made to its post-marketing commitments.
According to a statement released by the company, it plans to resubmit its application before the end of 2016.
Why Do Doctors Prescribe Xarelto And Without A Known Xarelto Antidote?
Blood thinners like Xarelto and Eliquis are used to prevent strokes and blood clots following surgery for people with atrial fibrillation.
Unlike warfarin, which has been used for decades, the non-vitamin K antagonist oral anticoagulants (NOACs) Xarelto, Eliquis, and Pradaxa do not require frequent blood tests or dietary restrictions.
The only other approved reversal agent for the NOACs, given by the FDA in October 2015, is Praxbind, an antidote for Pradaxa.
Given the fact that there is no Xarelto antidote, many physicians are wary of prescribing the new anticoagulants, since there is limited evidence on how to manage bleeding in patients taking Xarelto and there is no known reversal of the anticoagulant effect.
According to the Institute of Safe Medicines Practices (ISMP), a watchdog group, anticoagulant drugs are a “high-risk treatment” and cause bleeding in approximately 15% of patients with atrial fibrillation.
The lack of a specific antidote was one factor that led to over 4,000 lawsuits being filed against Boehringer Ingelheim, the maker of Pradaxa who recently agreed to pay $650 million to settle these lawsuits.
Xarelto is now the top prescribed anticoagulant in the U.S
Xarelto Lawsuits Move Forward
As the number of adverse events linked with these blood thinners rise, so do the lawsuits.
More than 7,200 federal lawsuits against the manufacturer of Eliquis are currently pending and have been consolidated into multidistrict litigation (MDL) 2592 in the District of Louisiana, and a mass tort program in the state of Pennsylvania, where more than 800 have been centralized.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
